Cargando…
Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
SARS-CoV-2-specific antibody responses are engendered in human milk after BNT162b2 vaccination. However, the emergence of variants of concern (VOCs) raises concerns about the specificity of and potential cross-protection mediated by milk antibody responses, which are crucial for passive immunity tra...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880232/ https://www.ncbi.nlm.nih.gov/pubmed/35214683 http://dx.doi.org/10.3390/vaccines10020225 |
_version_ | 1784659136170950656 |
---|---|
author | Low, Jia Ming Gu, Yue Ng, Melissa Shu Feng Wang, Liang Wei Amin, Zubair Zhong, Youjia MacAry, Paul A. |
author_facet | Low, Jia Ming Gu, Yue Ng, Melissa Shu Feng Wang, Liang Wei Amin, Zubair Zhong, Youjia MacAry, Paul A. |
author_sort | Low, Jia Ming |
collection | PubMed |
description | SARS-CoV-2-specific antibody responses are engendered in human milk after BNT162b2 vaccination. However, the emergence of variants of concern (VOCs) raises concerns about the specificity of and potential cross-protection mediated by milk antibody responses, which are crucial for passive immunity transferred from breastfeeding mothers to their infants. In this study, we collected milk samples at three different time points pre- and post-vaccination, and measured milk IgA antibody binding to the receptor binding domain (RBD) of the original Wuhan-Hu-1 strain, and the four VOCs, namely Alpha, Beta, Gamma and Delta. We report a significant level of anti-RBD IgA in milk collected at 4–6 weeks after the second dose of vaccination compared to pre-vaccination. We observed around a 30% reduction in binding to most VOCs, including the major circulating Delta variant, compared to the original Wuhan-Hu-1 strain. As COVID-19 vaccines may take some time to be approved for infants, these individuals remain at risk for severe disease and rely mainly on transferred passive immunity. Our findings support the current recommendations for vaccinating lactating women with the aim of transferring mucosal immunity to breastfeeding infants. |
format | Online Article Text |
id | pubmed-8880232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88802322022-02-26 Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern Low, Jia Ming Gu, Yue Ng, Melissa Shu Feng Wang, Liang Wei Amin, Zubair Zhong, Youjia MacAry, Paul A. Vaccines (Basel) Article SARS-CoV-2-specific antibody responses are engendered in human milk after BNT162b2 vaccination. However, the emergence of variants of concern (VOCs) raises concerns about the specificity of and potential cross-protection mediated by milk antibody responses, which are crucial for passive immunity transferred from breastfeeding mothers to their infants. In this study, we collected milk samples at three different time points pre- and post-vaccination, and measured milk IgA antibody binding to the receptor binding domain (RBD) of the original Wuhan-Hu-1 strain, and the four VOCs, namely Alpha, Beta, Gamma and Delta. We report a significant level of anti-RBD IgA in milk collected at 4–6 weeks after the second dose of vaccination compared to pre-vaccination. We observed around a 30% reduction in binding to most VOCs, including the major circulating Delta variant, compared to the original Wuhan-Hu-1 strain. As COVID-19 vaccines may take some time to be approved for infants, these individuals remain at risk for severe disease and rely mainly on transferred passive immunity. Our findings support the current recommendations for vaccinating lactating women with the aim of transferring mucosal immunity to breastfeeding infants. MDPI 2022-01-31 /pmc/articles/PMC8880232/ /pubmed/35214683 http://dx.doi.org/10.3390/vaccines10020225 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Low, Jia Ming Gu, Yue Ng, Melissa Shu Feng Wang, Liang Wei Amin, Zubair Zhong, Youjia MacAry, Paul A. Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern |
title | Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern |
title_full | Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern |
title_fullStr | Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern |
title_full_unstemmed | Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern |
title_short | Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern |
title_sort | human milk antibodies after bnt162b2 vaccination exhibit reduced binding against sars-cov-2 variants of concern |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880232/ https://www.ncbi.nlm.nih.gov/pubmed/35214683 http://dx.doi.org/10.3390/vaccines10020225 |
work_keys_str_mv | AT lowjiaming humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern AT guyue humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern AT ngmelissashufeng humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern AT wangliangwei humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern AT aminzubair humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern AT zhongyoujia humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern AT macarypaula humanmilkantibodiesafterbnt162b2vaccinationexhibitreducedbindingagainstsarscov2variantsofconcern |